Summit Therapeutics (SMMT) Income from Continuing Operations (2019 - 2024)
Summit Therapeutics (SMMT) reported Income from Continuing Operations of 65623000.0 for Q4 2024, down 81.23% on a YoY basis from 349596708.84 in Q1 2024, and down 7.88% quarter-over-quarter from 60832000.0 in Q3 2024.
Summit Therapeutics (SMMT) Income from Continuing Operations (2019 - 2024) Analysis & Trends
Summit Therapeutics has reported Income from Continuing Operations for 6 years, with the latest figure at 65623000.0 in Q4 2024.
- For the quarter ending Q4 2024, Income from Continuing Operations fell 81.23% year-over-year to 65623000.0; the trailing twelve-month figure through Dec 2024 stood at 234684000.0 (up 61.51% YoY), and the FY2024 full-year result was 234684000.0, up 61.84% from the prior year.
- Income from Continuing Operations for Q4 2024 stood at 65623000.0, down from 60832000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 6134000.0 in Q1 2020, with the low at 537154000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 52886100.0 across 5 years, with a median of 20395500.0 in 2022.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 2324.2% — and 2024, when it surged 91.53%.
- Summit Therapeutics' Income from Continuing Operations stood at 13541000.0 in 2020, then slumped by 100.13% to 27099000.0 in 2021, then climbed by 25.09% to 20299000.0 in 2022, then plunged by 78.38% to 36210000.0 in 2023, then tumbled by 81.23% to 65623000.0 in 2024.
- The last three Income from Continuing Operations figures came in at 65623000.0 (Q4 2024), 60832000.0 (Q3 2024), and 62719000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.62 Mn |
| Sep 30, 2024 | -60.83 Mn |
| Jun 30, 2024 | -62.72 Mn |
| Mar 31, 2024 | -45.51 Mn |
| Dec 31, 2023 | -36.21 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -537.15 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -22.16 Mn |
| Dec 31, 2021 | -27.10 Mn |
| Sep 30, 2021 | -19.60 Mn |
| Jun 30, 2021 | -24.42 Mn |
| Mar 31, 2021 | -17.49 Mn |
| Dec 31, 2020 | -13.54 Mn |
| Sep 30, 2020 | -17.74 Mn |
| Jun 30, 2020 | -15.28 Mn |
| Mar 31, 2020 | -6.13 Mn |